DHEA-S
Dehydroepiandrosterone Sulphate
What it is
DHEA-S (dehydroepiandrosterone sulphate) is the sulphated storage form of DHEA, an adrenal androgen precursor produced primarily by the zona reticularis of the adrenal cortex. It is the most abundant steroid hormone in human circulation, serving as the principal circulating reservoir for peripheral sex steroid production. In peripheral tissues — particularly skin, adipose, breast, and prostate — DHEA-S is desulphated to DHEA and then converted by local enzymes to androgens (testosterone, DHT) and oestrogens (oestradiol, oestrone), a process called intracrinology. DHEA-S is used in preference to DHEA for measurement because its half-life is approximately 7–10 hours (versus 15–30 minutes for DHEA), making its serum levels far more stable and reproducible across time of day and stress fluctuations. DHEA-S production peaks in the mid-20s and declines progressively with age at approximately 2–3% per year — a phenomenon termed adrenopause — so that by age 70, circulating DHEA-S has fallen to approximately 20–30% of its peak value.
Why we measure it
DHEA-S provides two clinically useful signals. First, it is an indirect measure of adrenal androgen output and overall steroid hormone reserve — a low DHEA-S for age indicates reduced adrenocortical reserve, reduced capacity for peripheral sex steroid production, and potential contribution to the fatigue, reduced libido, and muscle loss that accompany ageing. This is particularly relevant in perimenopausal and postmenopausal women, in whom adrenal DHEA becomes the primary source of androgens and oestrogens after ovarian function ceases. Second, markedly elevated DHEA-S — well above age-appropriate ranges — can indicate adrenal androgen excess. In females, this is a common finding in adrenal-source PCOS (characterised by elevated DHEA-S, elevated testosterone, menstrual irregularity, and androgenic symptoms), which has a different treatment approach from ovarian-source PCOS. Very high DHEA-S in adults may also indicate an adrenal tumour and warrants investigation. Annual DHEA-S measurement contextualises testosterone and oestradiol readings, and tracks the pace of biological ageing in the adrenocortical axis.
Why every 6 months
Unlike cortisol, DHEA-S does not exhibit a significant diurnal rhythm and can be measured at any consistent time. As the sulphated storage form, its levels are stable across the day. The six-month interval captures the slow age-related decline of adrenal androgen reserve and detects meaningful deviations from expected trajectory — particularly a DHEA-S that is falling faster than expected for age, suggesting accelerated adrenocortical ageing.
What movement means
DHEA-S reference ranges are strongly age-dependent and differ by sex. Ranges decline progressively across adult life; the ranges below represent approximate age-banded values for adult males and females. Laboratory-specific and age-stratified reference ranges should always be consulted.
Low for Age
Below age- and sex-specific lower reference limit
Below the expected range for the individual's age and sex. Associated with reduced adrenal androgen reserve, fatigue, impaired immune function, and — in postmenopausal women — reduced peripheral oestrogen production. Warrants assessment of adrenal function and review of modifiable factors (sleep, chronic stress, cortisol excess).
Age- and sex-specific reference ranges — vary by assay method and laboratory
Normal for Age
Within age- and sex-specific reference interval
Appropriate adrenal androgen output for the individual's age. Typical values in middle-aged adults (40–50 years): males approximately 2.2–13.9 μmol/L; females approximately 1.4–9.6 μmol/L. Values decline progressively with age.
Age- and sex-specific reference ranges — vary by assay method and laboratory
Elevated for Age
Above age- and sex-specific upper reference limit
Elevated DHEA-S in adult females often indicates adrenal androgen excess contributing to androgen-related symptoms (acne, hirsutism, menstrual irregularity). Very high DHEA-S in either sex warrants evaluation for adrenal pathology. Clinical assessment including testosterone, androstenedione, and adrenal imaging should be considered.
Azziz R et al., Journal of Clinical Endocrinology & Metabolism, 2004 — doi:10.1210/jc.2003-031360
In the protocol
References
- 1.
Orentreich N, Brind JL, Rizer RL, Vogelman JH. “Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations Throughout Adulthood.” Journal of Clinical Endocrinology & Metabolism. 1984.
- 2.
Labrie F. “Intracrinology in Action: Importance of Extragonadal Sex Steroid Biosynthesis and Inactivation in Peripheral Tissues in Both Genders.” Journal of Steroid Biochemistry and Molecular Biology. 2015.
- 3.
Azziz R, Carmina E, Dewailly D, et al.. “Positions Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome.” Journal of Clinical Endocrinology & Metabolism. 2006.
- 4.
Baulieu EE, Thomas G, Legrain S, et al.. “Dehydroepiandrosterone (DHEA), DHEA Sulfate, and Aging: Contribution of the DHEAge Study to a Sociobiomedical Issue.” Proceedings of the National Academy of Sciences. 2000.